Novo Nordisk

Novo Nordisk licenses kidney disease drug from Epigen
Fierce Biotech
Thu, 05/24/18 - 10:01 am
Novo Nordisk
Epigen
EPGN696
kidney disease
Novo Nordisk steps up interest in diabetes, Parkinson’s stem cell therapies
Fierce Biotech
Fri, 05/18/18 - 11:59 am
Novo Nordisk
type 1 diabetes
stem cells
Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborations
Endpoints
Thu, 05/17/18 - 10:04 am
Novo Nordisk
type 1 diabetes
stem cells
Biolamina
Novo Nordisk Fights Payer Pressure With New Meds
Motley Fool
Mon, 05/7/18 - 05:30 pm
Novo Nordisk
earnings
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
Fierce Pharma
Wed, 05/2/18 - 07:24 pm
Novo Nordisk
GLP-1 agonist
diabetes
Ozempic
drug launches
How a drug company under pressure for high prices ratchets up political activity
Stat
Mon, 04/30/18 - 12:11 pm
Novo Nordisk
drug pricing
Novo Nordisk tackles outcomes and affordability with pilot tying copays to adherence
Fierce Pharma
Wed, 04/18/18 - 11:07 pm
diabetes
patients
Novo Nordisk
drug discounts
outcomes-based pricing
Novo charts course for sickle cell amid headwinds in hemophilia
Biopharma Dive
Thu, 04/5/18 - 11:47 pm
Novo Nordisk
sickle cell disease
hemophilia
EPI01
EpiDestiny
FDA approves label update to Novo Nordisk’s Tresiba diabetes drug
Drug Delivery Business News
Mon, 03/26/18 - 10:39 pm
FDA
Novo Nordisk
diabetes
Tresiba
labeling
insulin degludec
Pharma's social media strategies are growing up—and working better, too, report finds
Fierce Pharma
Mon, 03/26/18 - 09:34 am
social media
Novo Nordisk
JNJ
Novartis
Boehringer Ingelheim
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Drug Delivery Business News
Fri, 03/23/18 - 09:45 am
Japan
Novo Nordisk
diabetes
type 2 diabetes
Ozempic
Drugmaker Novo Nordisk looks to former oil boss to energize M&A
Reuters
Thu, 03/22/18 - 11:10 am
Novo Nordisk
M&A
Helge Lund
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
Thu, 03/22/18 - 09:21 am
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Fierce Pharma
Mon, 03/19/18 - 11:40 pm
Novo Nordisk
obesity
semaglutide
GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk
Market Realist
Mon, 03/5/18 - 09:24 am
Novo Nordisk
GLP-1 agonist
diabetes
Victoza
[video]Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices
Bloomberg
Sun, 03/4/18 - 09:58 am
Novo Nordisk
Pharma CEOs
competition
drug pricing
Lars Fruergaard Jorgensen
Novo Nordisk secures Ozempic formulary coverage from Express Scripts
Fierce Pharma
Sat, 02/24/18 - 10:36 pm
Novo Nordisk
Ozempic
Express Scripts
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Fierce Pharma
Thu, 02/22/18 - 11:28 pm
migraines
NASH
Amgen
Eli Lilly
Teva Pharmaceutical
Allergan
Gilead Sciences
Novo Nordisk
Intercept Pharma
PBMs
In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug
Endpoints
Thu, 02/22/18 - 09:12 am
Novo Nordisk
Eli Lilly
diabetes
clinical trials
semaglutide
Trulicity
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Fierce Pharma
Mon, 02/12/18 - 11:00 am
Novo Nordisk
semaglutide
Eli Lilly
Ozempic
Trulicity

Pages